Companies Fulgent Genetics, Inc.
Fulgent Genetics (FLGT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Fulgent Genetics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers33rd pct.Of 12 peer CEOs
CEO pay, last three years
- $5,309,167FY2023
- $6,128,000FY2024
- $6,207,000FY2025
CEO total pay was $6,207,000 in fiscal 2025, up from $6,128,000 in fiscal 2024.
FY2025: salary $1,000,000 · bonus $0 · stock awards $4,000,000 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Fulgent Genetics, Inc. in fiscal 2025?
As disclosed, Ming Hsieh (Chief Executive Officer and Chairperson of the Board) was the highest-paid executive at Fulgent Genetics, Inc. in fiscal 2025, with total compensation of $6,207,000.
How does Fulgent Genetics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Ming Hsieh's total compensation ranked at the 33rd percentile of Fulgent Genetics, Inc.'s disclosed peer group.
What is Fulgent Genetics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Fulgent Genetics, Inc.'s CEO-to-median employee pay ratio was 92:1.
How did shareholders vote on Fulgent Genetics, Inc.'s executive compensation?
As disclosed, 89.15% of shareholders supported Fulgent Genetics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Fulgent Genetics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Fulgent Genetics, Inc. reported total board compensation of $767,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ming Hsieh | $1,000,000 | $0 | $4,000,000 | $0 | $1,207,000 | $0 | $0 | $6,207,000 |
| Chief Executive Officer and Chairperson of the Board | ||||||||
| Jian Xie | 615,000 | 0 | 1,845,000 | 0 | 334,037 | 0 | 13,621 | 2,807,658 |
| President and Chief Operating Officer | ||||||||
| Paul Kim | 600,000 | 0 | 1,800,000 | 0 | 325,890 | 0 | 47,462 | 2,773,352 |
| Chief Financial Officer | ||||||||
| Hanlin Gao | 513,000 | 0 | 1,539,000 | 0 | 278,636 | 0 | 21,613 | 2,352,249 |
| Chief Scientific Officer and Laboratory Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ming Hsieh | $6,207,000 | $6,128,000 | $5,309,167 | ↑ +79,000 |
| Jian Xie | 2,807,658 | 2,375,795 | 1,791,241 | ↑ +431,863 |
| Paul Kim | 2,773,352 | 2,353,644 | 1,779,613 | ↑ +419,708 |
| Hanlin Gao | 2,352,249 | 1,981,978 | 1,490,202 | ↑ +370,271 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The goal of our executive compensation philosophy is to deliver competitive levels of total compensation that attract and retain top leadership talent, with primary emphasis on pay for performance. Base salary is targeted at the 50th percentile of market pay, while variable incentive pay is earned based on performance measured over short-term and long-term periods to align executive interests with stockholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | USI |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Paul Kim | RSU | 2025-02-25 | — | — | 44,199 | — | $720,000 |
| Ming Hsieh | PSU | 2025-02-25 | 36,832 | 147,329 | — | 239,410 | 2,400,000 |
| Jian Xie | RSU | 2025-02-25 | — | — | 45,304 | — | 738,000 |
| Hanlin Gao | PSU | 2025-02-25 | 14,171 | 56,685 | — | 92,113 | 923,400 |
| Jian Xie | PSU | 2025-02-25 | 16,989 | 67,956 | — | 110,429 | 1,107,000 |
| Ming Hsieh | RSU | 2025-02-25 | — | — | 98,220 | — | 1,600,000 |
| Paul Kim | PSU | 2025-02-25 | 16,575 | 66,298 | — | 107,734 | 1,080,000 |
| Hanlin Gao | RSU | 2025-02-25 | — | — | 37,790 | — | 615,600 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Paul Kim | $720,000 | $1,080,000 | $0 | 60.0% |
| Ming Hsieh | 1,600,000 | 2,400,000 | 0 | 60.0% |
| Jian Xie | 738,000 | 1,107,000 | 0 | 60.0% |
| Hanlin Gao | 615,600 | 923,400 | 0 | 60.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Hanlin Gao | RSU | 131,497 | — | $3,454,426 |
| Paul Kim | RSU | 153,459 | — | 4,031,368 |
| Jian Xie | RSU | 157,245 | — | 4,130,826 |
| Ming Hsieh | RSU | 358,727 | — | 9,423,758 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Regina GrovesIndependent · Audit (Chair) · Compensation · Nominating/Governance | $108,000 | $180,000 | $0 | $0 | $0 | $288,000 |
| Linda DongIndependent · Audit · Compensation (Chair) · Nominating/Governance · Partial-year service | 105,500 | 180,000 | 0 | 0 | 0 | 285,500 |
| Michael NohaileIndependent · Audit · Compensation · Nominating/Governance (Chair) · Partial-year service | 103,500 | 90,000 | 90,000 | 0 | 0 | 283,500 |
Board fee structure and ownership guideline
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $180,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 6,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $317,000 |
| Equity awards (grant-date value) | $450,000 |
| All other compensation | $0 |
| Total cost of the board | $767,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Fulgent Genetics as a peer
Companies that benchmark against FLGT
12 companies name FLGT as a compensation peer
- Adaptive Biotechnologies CorpADPTFY2025
- CareDx, Inc.CDNAFY2025
- Chrome Holding Co.MEFY2024
- iRhythm Holdings, Inc.IRTCFY2025
- MARAVAI LIFESCIENCES HOLDINGS, INC.MRVIFY2025
- NEOGENOMICS INCNEOFY2025
- ORASURE TECHNOLOGIES INCOSURFY2025
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACBFY2025
- Personalis, Inc.PSNLFY2025
- VERACYTE, INC.VCYTFY2025
Each company listed discloses FLGT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named FLGT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
NEO NeoGenomics, Inc.ADPT Adaptive Biotechnologies CorporationTXG 10x Genomics, Inc.PACB Pacific Biosciences of California, Inc.MYGN Myriad Genetics, Inc.CDNA CareDx, Inc.CSTL Castle Biosciences, Inc.CTKB Cytek Biosciences, Inc.WGS GeneDx Holdings Corp.OPK Opko Health, Inc.TWST Twist Bioscience CorporationVCYT Veracyte, Inc.
Peer reciprocity
The companies Fulgent Genetics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
NeoGenomics, Inc. (NEO)65Adaptive Biotechnologies Corporation (ADPT)66Pacific Biosciences of California, Inc. (PACB)67CareDx, Inc. (CDNA)68Veracyte, Inc. (VCYT)69
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Twist Bioscience Corporation | 2025 | Emily Leproust | $720,000 | $11,998,134 | $0 | $932,918 | $13,781,570 |
| 2 | GeneDx Holdings Corp. | 2025 | Katherine Stueland | 715,869 | 11,738,600 | 0 | 1,075,500 | 13,547,219 |
| 3 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 4 | Adaptive Biotechnologies Corporation | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 5 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 6 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 7 | Castle Biosciences, Inc. | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 8 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 9 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 10 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 11 | Cytek Biosciences, Inc. | 2025 | Wenbin Jiang | 620,000 | 2,000,000 | 2,000,000 | 485,211 | 5,120,061 |
| 12 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 13 | Opko Health, Inc. | 2025 | Phillip Frost | 960,000 | 0 | 400,000 | 0 | 1,854,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Adaptive Biotechnologies Corporation | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Castle Biosciences, Inc. | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Cytek Biosciences, Inc. | 78.4% | RSU 50 · Options 50 | not disclosed | Meridian Compensation Partners, LLC |
| GeneDx Holdings Corp. | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Opko Health, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 19,800,226 | 2,410,239 | 45,478 | 89.15% | Passed |
| 2025 | 2025-05-15 | 16,269,463 | 3,814,788 | 60,433 | 81.01% | Passed |
| 2024 | 2024-05-16 | 19,786,239 | 573,411 | 25,950 | 97.18% | Passed |
| 2023 | 2023-05-18 | 18,882,872 | 607,633 | 101,007 | 96.38% | Passed |
| 2022 | 2022-05-18 | 15,719,000 | 405,690 | 99,733 | 97.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-14 | 89.15%a |
| 2025 | 2025-05-15 | 81.01%b |
| 2024 | 2024-05-16 | 97.18%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 92 : 1 |
|---|---|
| CEO total compensation | $6,207,000 |
| Median employee compensation | $67,465 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Paul Kim | CFO and Treasurer | 2026-04-26 | D | 2,747 | $16 | $44,804 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-04-26 | D | 1,645 | 16 | 26,830 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-04-26 | D | 4,361 | 16 | 71,128 | Common | Form 4 ↗ |
| Regina Groves | Director | 2026-05-14 | A | 11,117 | 0 | 0 | Common | Form 4 ↗ |
| Linda Dong | Director | 2026-05-14 | A | 11,117 | 0 | 0 | Common | Form 4 ↗ |
| Michael Nohaile | Director | 2026-05-14 | A | 8,426 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Nohaile | Director | 2026-05-14 | A | 5,558 | 0 | 0 | Common | Form 4 ↗ |
| Ming Hsieh | Director | 2026-05-26 | D | 2,949 | 18 | 52,109 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-05-26 | D | 1,168 | 18 | 20,639 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-05-27 | D | 1,201 | 18 | 21,138 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-05-27 | D | 945 | 18 | 16,632 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-06-01 | D | 2,087 | 18 | 37,754 | Common | Form 4 ↗ |
| Ming Hsieh | Director | 2026-06-01 | D | 4,392 | 18 | 79,451 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-06-02 | D | 1,688 | 18 | 30,191 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-06-02 | D | 2,146 | 18 | 38,382 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-07-26 | D | 1,645 | 20 | 32,357 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-07-26 | D | 4,361 | 20 | 85,781 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-07-26 | D | 2,747 | 20 | 54,033 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-08-26 | D | 1,168 | 20 | 23,138 | Common | Form 4 ↗ |
| Ming Hsieh | Director | 2026-08-26 | D | 2,949 | 20 | 58,420 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-08-27 | D | 939 | 20 | 18,691 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-08-27 | D | 1,193 | 20 | 23,747 | Common | Form 4 ↗ |
| Ming Hsieh | Director | 2026-09-01 | D | 4,392 | 20 | 86,039 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-09-01 | D | 2,087 | 20 | 40,884 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-09-02 | D | 2,127 | 20 | 41,809 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-09-02 | D | 1,673 | 20 | 32,885 | Common | Form 4 ↗ |
| Jian Xie | President and COO | 2026-10-26 | D | 4,361 | 20 | 88,179 | Common | Form 4 ↗ |
| Paul Kim | CFO and Treasurer | 2026-10-26 | D | 2,748 | 20 | 55,565 | Common | Form 4 ↗ |
| Hanlin Gao | Chief Scientific Officer | 2026-10-26 | D | 1,645 | 20 | 33,262 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (69 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ming Hsieh. DEF 14A, filed 2026-03-31. Section “Executive Compensation” · page 30. As printed: 6,207,000. View filing ↗
- Section 01, Jian Xie. DEF 14A, filed 2026-03-31. Section “Executive Compensation”. As printed: 2,807,658. View filing ↗
- Section 01, Paul Kim. DEF 14A, filed 2026-03-31. Section “Executive Compensation”. As printed: 2,773,352. View filing ↗
- Section 01, Hanlin Gao. DEF 14A, filed 2026-03-31. Section “Executive Compensation”. As printed: 2,352,249. View filing ↗
- Section 03, Paul Kim RSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ming Hsieh PSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jian Xie RSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hanlin Gao PSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jian Xie PSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ming Hsieh RSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Kim PSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hanlin Gao RSU. DEF 14A, filed 2026-03-31. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-31. Section “CEO Pay Ratio”. As printed: 92 : 1. View filing ↗
- Section 08, Regina Groves. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 288,000. View filing ↗
- Section 08, Linda Dong. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 285,500. View filing ↗
- Section 08, Michael Nohaile. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 283,500. View filing ↗
- Section 02, Paul Kim 2026-04-26. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-04-26. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-04-26. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Regina Groves 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Dong 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Nohaile 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Nohaile 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ming Hsieh 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ming Hsieh 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-07-26. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-07-26. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-07-26. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ming Hsieh 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ming Hsieh 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jian Xie 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kim 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hanlin Gao 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-14. Item 5.07 · say-on-pay result. As reported: 89.15% (votes for as printed: 19,800,226). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-15. Item 5.07 · say-on-pay result. As reported: 81.01% (votes for as printed: 16,269,463). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-16. Item 5.07 · say-on-pay result. As reported: 97.18% (votes for as printed: 19,786,239). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 317,000 + equity 450,000 + all other 0 = 767,000, summed across the director compensation table rows.
- Twist Bioscience Corporation, Section 10b CEO total. DEF 14A, filed 2026-01-06. CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. View filing ↗
- GeneDx Holdings Corp., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in GeneDx Holdings Corp.'s own proxy. As printed: 13,547,219. View filing ↗
- NeoGenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
- Adaptive Biotechnologies Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. View filing ↗
- Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
- CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Castle Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. View filing ↗
- 10x Genomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. View filing ↗
- Fulgent Genetics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. View filing ↗
- Myriad Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. View filing ↗
- Cytek Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cytek Biosciences, Inc.'s own proxy. As printed: 5,120,061. View filing ↗
- Pacific Biosciences of California, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. View filing ↗
- Opko Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Opko Health, Inc.'s own proxy. As printed: 1,854,000. View filing ↗
- Section 10a, NeoGenomics, Inc. reciprocity. DEF 14A. NeoGenomics, Inc. names Fulgent Genetics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Adaptive Biotechnologies Corporation reciprocity. DEF 14A. Adaptive Biotechnologies Corporation names Fulgent Genetics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Pacific Biosciences of California, Inc. reciprocity. DEF 14A. Pacific Biosciences of California, Inc. names Fulgent Genetics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, CareDx, Inc. reciprocity. DEF 14A. CareDx, Inc. names Fulgent Genetics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Veracyte, Inc. reciprocity. DEF 14A. Veracyte, Inc. names Fulgent Genetics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗